Vikse et al. Norwegian case series of 40 patients treated with RTX for IgG4-RD. Efficacy across phenotypes 80-100% for improvement but only 45-78% for remission. @rheumnow #ACR22 Abstr#0147 https://t.co/J7b47ywbt0 https://t.co/pfhOIG5qXk
Links:
Rituximab in IgG4-Related Diseae: An Open-Label Non-Randomized Observational St…
https://acrabstracts.org/abstract/rituximab-in-igg4-related-diseae-an-open-labe…
12-11-2022